Provenge + CT-011 + cyclophosphamide in treatment of mCRPC

The Georgia Health Sciences University in Augusta, GA, has initiated a new trial of sipuleucel-T (Provenge) in combination with cyclophosphamide and an investigational drug known as CT-011 for the treatment of chemotherapy-naive patients with progressive, metastatic, castrate-resistant prostate cancer (mCRPC). … READ MORE …